Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control.

Autor: Anderson J; The Frist Clinic, 2400 Patterson Street, Suite 400, Nashville, TN, USA. Electronic address: jeamd89@gmail.com., Meneghini L; University of Texas Southwestern Medical Center and Parkland Health & Hospital System, 5323 Harry Hines Boulevard, Dallas, TX, USA. Electronic address: Luigi.Meneghini@sanofi.com., Hinnen D; Memorial Hospital Diabetes Center, University of Colorado Health, 175 S Union Boulevard, Suite 305, Colorado Springs, CO, USA. Electronic address: dh@sugar3rn.com., Gill J; Sanofi, 55 Corporate Drive, Bridgewater, NJ, USA. Electronic address: jasvinder.gill@sanofi.com., Coudert M; Sanofi, 1 Avenue Pierre Brossolette, Chilly-Mazarin, France. Electronic address: Mathieu.Coudert@sanofi.com., Evenou P; Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, UK. Electronic address: Pierre.Evenou@sanofi.com., Munshi M; Joslin Diabetes Center, 1 Joslin Place, Boston, MA, USA. Electronic address: mmunshi@bidmc.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of diabetes and its complications [J Diabetes Complications] 2021 Apr; Vol. 35 (4), pp. 107831. Date of Electronic Publication: 2020 Dec 31.
DOI: 10.1016/j.jdiacomp.2020.107831
Abstrakt: Aims: To better understand outcomes in people with type 2 diabetes at high risk of hypoglycemia, we conducted post hoc analyses in subgroups of participants from the real-world ACHIEVE Control study (NCT02451137) with ≥1 hypoglycemia risk factor.
Methods: Insulin-naive adults with type 2 diabetes and A1c ≥8% were randomized 1:1 to insulin glargine 300 U/mL (Gla-300) or standard-of-care basal insulin (SOC-BI). Participants had documented history of ≥1 risk factors for hypoglycemia: chronic kidney disease, cardiovascular disease, dementia or blindness, age ≥65 years, or history of hypoglycemia. Outcomes included individualized A1c target attainment without documented symptomatic hypoglycemia (blood glucose [BG] ≤3.9 mmol/L or <3.0 mmol/L) or severe hypoglycemia, A1c target attainment, and absence of documented symptomatic or severe hypoglycemia at 6 and 12 months.
Results: Within subgroups, odds ratios generally showed trends favoring Gla-300 versus SOC-BI, particularly for hypoglycemia avoidance in participants ≥65 years of age (BG ≤3.9 mmol/L; odds ratio, 1.52; 95% confidence interval, 1.14-2.03) and those with chronic kidney disease (BG ≤3.9 mmol/L; odds ratio, 2.28; 95% confidence interval, 1.26-4.12). Results were consistent with the overall population.
Conclusions: These data suggest potential benefit of Gla-300 versus SOC-BI for avoiding hypoglycemia in participants with ≥1 hypoglycemia risk factor.
(Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: